(Riya Singh, Intern Journalist): Pharma major Cipla said on Wednesday it has released its generic version of antiviral drug remdesivir at Rs 4,000 per vial, which is the lowest in the world, and is aiming to produce more than 80,000 vials within the first month.
The drug would only be distributed via government and hospital outlets to ensure an equal delivery. Cipla will also donate a certain amount of the medication as part of its efforts to help the society in this hourly need.
The Drug Controller General of India (DCGI) has approved Cipremi for restricted emergency use in the country as part of the accelerated approval process recognizing the immediate and unmet medical requirement. Remdesivir is the only U.S. Food and Drug Administration (USFDA) authorized Emergency Use Authorization (EUA) medication for adult and pediatric patients diagnosed with reported Covid-19 infection or confirmed by laboratory.
In May, domestic pharmaceutical companies Hetero, Cipla and Jubilant Life Sciences entered into non-exclusive license agreements for the production and sale of remdesivir with drug giant Gilead Sciences Inc.
About Post Author
